266 related articles for article (PubMed ID: 20807811)
1. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
[TBL] [Abstract][Full Text] [Related]
2. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
3. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
6. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
7. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
12. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
Carboni JM; Wittman M; Yang Z; Lee F; Greer A; Hurlburt W; Hillerman S; Cao C; Cantor GH; Dell-John J; Chen C; Discenza L; Menard K; Li A; Trainor G; Vyas D; Kramer R; Attar RM; Gottardis MM
Mol Cancer Ther; 2009 Dec; 8(12):3341-9. PubMed ID: 19996272
[TBL] [Abstract][Full Text] [Related]
13. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
[TBL] [Abstract][Full Text] [Related]
15. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
Surmacz E
Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
[TBL] [Abstract][Full Text] [Related]
16. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
Kalebic T; Tsokos M; Helman LJ
Cancer Res; 1994 Nov; 54(21):5531-4. PubMed ID: 7923191
[TBL] [Abstract][Full Text] [Related]
17. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
19. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
Cao L; Yu Y; Darko I; Currier D; Mayeenuddin LH; Wan X; Khanna C; Helman LJ
Cancer Res; 2008 Oct; 68(19):8039-48. PubMed ID: 18829562
[TBL] [Abstract][Full Text] [Related]
20. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
